OctreoPharm Sciences GMBH
Radiolabeled diagnostics and treatments for neuroendocrine tumors
This article was originally published in Start Up
The founders of OctreoPharm Sciences GMBH aim to commercialize new kinds of radiolabeled pharmaceuticals to treat all kinds of neuroendocrine tumors, plus matching diagnostics to improve physicians’ ability to detect and monitor these rare cancers. Beyond exclusive rights to relevant intellectual property, the founders’ backgrounds suggest they possess skills appropriate to the task
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.